{"prompt": "['Novartis', 'Confidential', 'Page 22', 'Clinical Trial Protocol (Version 00)', 'Protocol No. CQAW039A2317', 'at baseline. In one study, QAW039 also demonstrated a reduction in sputum eosinophils in', 'patients with severe asthma.', 'The potential benefits of QAW039 therapy need to be balanced against its potential risks.', 'Potential side effects of QAW039 include: increased heart rate, non-serious arrhythmia such', 'as palpitations, headache, diarrhea, nausea, vomiting, nasopharyngitis, somnolescence and', 'dizziness. In humans, one major metabolite of QAW039 has been identified which is formed', 'by glucuronidation (acyl glucuronide) and partially binds to plasma proteins. In the literature,', 'in vivo binding of acyl glucuronides to proteins has been reported to be associated with rare', 'idiosyncratic drug reactions (IDRs), although a causal connection of protein adduction to', 'IDRs remains uncertain (Regan et al 2010). There have been no IDRs observed with', 'QAW039 treatment in completed clinical trials as of 31-Jan-2016. Taking QAW039 at the', 'doses used in this study with the cholesterol-lowering drug simvastatin has been shown to', 'cause a small increase in the peak blood level of simvastatin.', 'The risk to patients in this trial will be minimized by compliance with the eligibility criteria', 'and study procedures and close clinical monitoring.', 'Patients on doses of simvastatin > 20 mg, doses of atorvastatin >40 mg, doses of', 'pravastatin >40 mg, or doses of pitavastatin >2 mg per day (Elsby et al 2012, Deng et al 2008,', 'Noe et al 2007, and Kalliokoski and Niemi 2009), as well as patients on any statins with high', 'creatine kinase (CK) levels (>2 X ULN (upper limit of normal)) at screening will be excluded', 'from the study. Patients on statin medication who are included in the study will have regular', 'monitoring for relevant symptoms and be subject to discontinuation based on persistent', 'myalgia and/or blood CK levels (Jacobson 2008). Cardiovascular risks will be monitored', 'based on changes in vital signs, ECGs and biochemical parameters. Monitoring of liver', 'function tests (LFT) and renal function will be conducted as described in Appendix 2 and', 'Appendix 3, respectively, of this protocol. Surveillance of adverse events for identification of', 'idiosyncratic drugs will be conducted.', \"Refer to the QAW039 Investigator's Brochure for further information about risks and\", 'benefits.', '4', 'Population', 'The study population will include:', 'Males and females aged >12 years.', 'Asthma patients who are already receiving ICS or ICS with one asthma controller', 'medication (see inclusion criterion 4 for allowed ICS doses and combinations) are the', 'target population for this study.', 'Approximately 1857 patients will be screened to randomize approximately 650 patients in', 'a 1:1 ratio into the study worldwide.', 'An estimated 15% of patients will discontinue their study drug during the treatment period;', 'these patients will not be replaced.', '4.1', 'Inclusion criteria', 'Patients eligible for inclusion in this study must fulfill all of the following criteria:']['Novartis', 'Confidential', 'Page 23', 'Clinical Trial Protocol (Version 00)', 'Protocol No. CQAW039A2317', '1. Written informed consent and assent (if applicable) must be obtained within 14 days prior', 'to or at Visit 1 before any assessment is performed including any adjustment to asthma', 'medication.', '2. Male and female patients at a minimum age of 12 years (or higher minimum age limit as', 'allowed by health authority and/or independent ethics committee/institutional review', 'board (IEC/IRB) approvals).', '3. Patients must have a diagnosis of asthma (according to GINA 2016) for a period of at least', '6 months prior to Visit 1.', '4. Patients who have been treated with:', 'Medium dose ICS, or', 'High dose ICS, or', 'Low dose ICS plus long-acting beta agonist (LABA), or', 'Low dose ICS plus leukotriene receptor antagonist (LTRA), or', 'Medium dose ICS plus LABA.', 'for at least 3 months prior to Visit 1 and the doses have been stable for at least 4 weeks', 'prior to Visit 1.', '5. For patients aged >18 years, FEV1 of 85% of the predicted normal value for the patient,', 'after withholding bronchodilators at Visit 1 and Visit 101. For patients aged 12 to <18', 'years, FEV1 of 90% of the predicted normal value for the patient, after withholding', 'bronchodilators at Visit 1 and Visit 101.', 'NOTE: Withholding of bronchodilators prior to spirometry:', 'Short-acting \u00df2-agonists (SABAs) > 6 hours;', 'Long-acting \u00df2-agonists (LABAs) given twice daily > 12 hours;', 'LABAs given once daily > 24 hours;', 'Fixed dose combinations (FDC) of LABA and ICS given twice daily > 12 hours; and', 'Fixed dose combinations of LABA and ICS given once daily > 24 hours.', '6.', 'Patients must have a daytime asthma symptom score (0 to 6 scale) of >1 per day during 4', 'of the last 7 days of the placebo run-in period.', '7.', 'Patients must have a total daily SABA use >1 puff per day during 4 of the last 7 days of', 'the placebo run-in period.', '8. Demonstrated reversible airway obstruction as determined by the central reader from the', 'spirometry vendor at Visit 1 or Visit 101. Reversibility is defined as an increase of >12%', 'and >200 ml in FEV1 approximately 10 to 15 minutes after administration of 400 mcg of', 'salbutamol/albuterol (or equivalent). Spacer devices are permitted for administration of', 'salbutamol/albuterol (or equivalent) during reversibility testing only. The Investigator or', 'delegate may decide whether or not to use a spacer for the reversibility testing.', 'If reversibility is not demonstrated at Visit 1, reversibility will be attempted at Visit', '101. If not achieved at Visit 101, then one additional attempt to demonstrate', 'reversibility is permitted within 4 days following Visit 101 in an ad 1-hoc visit to meet', 'this eligibility criterion.']\n\n###\n\n", "completion": "END"}